HOXC10 Overexpression

CI-VAR-00003222Explore in graph →CIViC 3646

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Glioma2
HOXC10 Overexpression	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID10147 Public glioma datasets were analyzed from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus. HOXC10 was seen to be significantly elevated in gliomas compared to non-tumor brain tissues, a… (full text at CIViC) PMID 30429891 · Tan et al., 2018 · Open in CIViC	civic
HOXC10 Overexpression	Bevacizumab	Predictive	D	Supports Sensitivity Response	3	submitted	EID9949 In determining the mechanisms of angiogenesis in gliomas, an in-depth preclinical analysis of HOXC10 overexpression in response to a vascular endothelial growth factor A (VEGFA) inhibitor bevacizumab … (full text at CIViC) PMID 30429891 · Tan et al., 2018 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.